Ratio Revelations: Pyxis Oncology Inc (PYXS)’s Financial Metrics in the Spotlight

Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Pyxis Oncology Inc (NASDAQ: PYXS) closed the day trading at $3.37 down -0.30% from the previous closing price of $3.38. In other words, the price has decreased by -$0.30 from its previous closing price. On the day, 1.21 million shares were traded. PYXS stock price reached its highest trading level at $3.43 during the session, while it also had its lowest trading level at $3.3.

Ratios:

For a better understanding of PYXS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.19 and its Current Ratio is at 12.19. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.11.

On February 09, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $8.

On January 23, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $12.Leerink Partners initiated its Outperform rating on January 23, 2024, with a $12 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 28 ’23 when Connealy Pamela Ann bought 8,000 shares for $1.87 per share. The transaction valued at 14,960 led to the insider holds 818,532 shares of the business.

Connealy Pamela Ann bought 6,426 shares of PYXS for $11,868 on Sep 27 ’23. The CFO and COO now owns 810,532 shares after completing the transaction at $1.85 per share. On Sep 27 ’23, another insider, Wadhane Jitendra, who serves as the Chief Accounting Officer of the company, bought 2,500 shares for $1.87 each. As a result, the insider paid 4,675 and bolstered with 226,937 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PYXS now has a Market Capitalization of 198454240 and an Enterprise Value of 62206156. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.29 while its Price-to-Book (P/B) ratio in mrq is 1.08. Its current Enterprise Value per Revenue stands at 3.853 whereas that against EBITDA is -1.012.

Stock Price History:

Over the past 52 weeks, PYXS has reached a high of $6.85, while it has fallen to a 52-week low of $1.35. The 50-Day Moving Average of the stock is -19.09%, while the 200-Day Moving Average is calculated to be 3.96%.

Shares Statistics:

Over the past 3-months, PYXS traded about 533.78K shares per day on average, while over the past 10 days, PYXS traded about 520430 shares per day. A total of 58.89M shares are outstanding, with a floating share count of 47.32M. Insiders hold about 19.65% of the company’s shares, while institutions hold 45.51% stake in the company. Shares short for PYXS as of 1715731200 were 1964095 with a Short Ratio of 4.11, compared to 1713139200 on 2208360. Therefore, it implies a Short% of Shares Outstanding of 1964095 and a Short% of Float of 4.19.

Earnings Estimates

At present, 6.0 analysts are actively evaluating the performance of Pyxis Oncology Inc (PYXS) in the stock market.On average, analysts expect EPS of -$0.32 for the current quarter, with a high estimate of -$0.27 and a low estimate of -$0.35, while EPS last year was -$0.41. The consensus estimate for the next quarter is -$0.29, with high estimates of -$0.15 and low estimates of -$0.35.

Analysts are recommending an EPS of between -$0.63 and -$1.43 for the fiscal current year, implying an average EPS of -$1.06. EPS for the following year is -$1.28, with 6.0 analysts recommending between -$1.06 and -$1.49.

Most Popular